Bausch & Lomb (TSX:BLCO) YoY EBITDA Growth : -116.78% (As of Mar. 2025)

View and export this data going back to 2022. Start your Free Trial

What is Bausch & Lomb YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Bausch & Lomb's YoY EBITDA Growth for the quarter that ended in Mar. 2025 was -116.78%.

Bausch & Lomb's EBITDA per Share for the three months ended in Mar. 2025 was C$-0.08.

Bausch & Lomb YoY EBITDA Growth Historical Data

The historical data trend for Bausch & Lomb's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bausch & Lomb YoY EBITDA Growth Chart

Bausch & Lomb Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

YoY EBITDA Growth

Get a 7-Day Free Trial

-23.61

0.07

-13.47

-17.67

27.43

Bausch & Lomb Quarterly Data
	Dec19	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
YoY EBITDA Growth	Get a 7-Day Free Trial														36.61	6.00	22.78	29.97	-116.78

Bausch & Lomb YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Bausch & Lomb's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

	YoY EBITDA Growth (A: Dec. 2024 )
=	(EBITDA per Share (A: Dec. 2024 )	-	EBITDA per Share (A: Dec. 2023 ))	/	\| EBITDA per Share (A: Dec. 2023 ) \|
=	(2.434	-	1.91)	/	\| 1.91 \|
=	27.43 %

Bausch & Lomb's YoY EBITDA Growth for the quarter that ended in Mar. 2025 is calculated as:

	YoY EBITDA Growth (Q: Mar. 2025 )
=	(EBITDA per Share (Q: Mar. 2025 )	-	EBITDA per Share (Q: Mar. 2024 ))	/	\| EBITDA per Share (Q: Mar. 2024 )) \|
=	(-0.077	-	0.459)	/	\| 0.459 \|
=	-116.78 %

Bausch & Lomb YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Bausch & Lomb's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Bausch & Lomb Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bausch & Lomb Corp (TSX:BLCO) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

BLCO:USA

Address

520 Applewood Crescent, Vaughan, ON, CAN, L4K 4B4

Website

https://www.bausch.com

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Executives